Intelligent Bio Solutions Nears U.S. Launch of Non-Invasive Drug Screening System
Intelligent Bio Solutions Nears U.S. Launch of Non-Invasive Drug Screening System
Key Takeaways (TLDR)
INBS poised for 2025 U.S. launch with non-invasive drug screening system, offering potential first-mover advantage in diverse industries.
INBS preparing for U.S. launch with FDA 510(k) submission, showing 94.1% accuracy in detecting opiates via fingerprint sweat.
INBS' non-invasive drug screening system contributes to a safer environment by enabling rapid and accurate detection of recent drug use.
INBS's Intelligent Fingerprinting Drug Screening System gaining global traction for its innovative approach to combating drug use.
Why it Matters
This news highlights the innovative technology of Intelligent Bio Solutions and its potential impact on drug screening processes in diverse industries. The company's expansion and FDA clearance progress signal a significant advancement in non-invasive testing methods, promising increased efficiency and accuracy.
Summary
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company, is progressing towards a 2025 U.S. launch of its non-invasive Intelligent Fingerprinting Drug Screening System. The system, with a 94.1% accuracy in detecting opiates through fingerprint sweat, is gaining global adoption across various industries.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Intelligent Bio Solutions Nears U.S. Launch of Non-Invasive Drug Screening System.